TNF Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Share-based Payments (Tables)

6 Months Ended

Jun. 30, 2019

The following table summarizes the option activities for the six months ended June 30, 2019:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		10,502		$	30.41	$	17.42		1.43	$	-
Granted		-			-		-		-		-
Exercised		-			-		-		-		-
Forfeited		(6,438	)		33.79		23.72		0.58		-
Canceled/Expired		-			-		-		-		-
Balance at June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-
Exercisable as of June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-

A summary of activity related to RSUs for the three months ended June 30, 2019 is presented below:

	Number of RSUs		Weighted Average Grant Date Fair Value
Balance at December 31, 2018		-	$	-
Granted		374,481	$	0.97
Exercised		-		-
Forfeited		-		-
Canceled/Expired		-		-
Balance at June 30, 2019		374,481	$	0.97
Exercisable as of June 30, 2019		-		-

The table below summarizes the warrant activity for the period ended June 30, 2019:

	Number of Warrants		Weighted Average Exercise Price		Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		2,110,737	$	3.10		4.21	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Canceled/Expired		-		-		-		-
Balance at June 30, 2019		2,110,737	$	3.10		3.71	$	-
Exercisable as of June 30, 2019		2,110,737	$	3.10		3.71	$	-